Our Blogs

• 23 Dec

  Your Questions Answered - December 2021 Teleconference Q&A

  23 Dec

  Questions and Answers for the December 2021 Gold Members' Teleconference.

  By Brian Dennehy

  Membership Access | gold

  Q&A

• 20 Dec

  Gold Members' Teleconference December 2021

  20 Dec

  2021 Market Recap - Mania Chronicles - Interest Rates - US Focus - 2022 Outlook - Market Update

  By Brian Dennehy

  Membership Access | gold

  Teleconference

• 17 Dec

  Best and Worst Funds in 2021

  17 Dec

  Here we look at the 20 Best and Worst funds this year. The wide range of funds emphasises how important fund selection is to your investing success.

  By Brian Dennehy

  Membership Access | free

  Fund analysis

• 17 Dec

  Best and Worst Sectors in 2021

  17 Dec

  In this blog, we look at the winning sectors for 2021, as well as those who had a more torrid time.

  By Ben Debney

  Membership Access | gold

  Sector analysis

• 17 Dec

  Three Dimensions Of Global Performance 2021

  17 Dec

  This analysis is more interesting this year than in prior years. We look at the performance of global stock markets in three different ways:

  By Ruairi Dennehy

  Membership Access | gold

  Market commentary

• 10 Dec

  AXA Guest Blog – Gene Editing – the biotech bringing new investment opportunities

  10 Dec

  The coronavirus pandemic has made biotechnology front page news. The arrival of multiple vaccines in record time has starkly highlighted how innovative – and versatile – the sector can be.

  By Guest Blog

  Membership Access | free

  Guest Blog

• 10 Dec

  Outrageous Predictions for 2022 – Revolution

  10 Dec

  Last week Saxo Bank released their “10 Outrageous Predictions for 2022”. These predictions are ‘unlikely’ events which could cause considerable disruption in markets, and are particularly relevant with the unpredictable COVID-19 crisis in mind.

  By Ben Debney

  Membership Access | gold

  Market commentary

• 10 Dec

  2021 The Year Of Biotech

  10 Dec

  In the last two years we have all become more appreciative of not just the work of our NHS, but also the extraordinary scientists who typically sit in the background. It is time for us to revisit the biotech funds.

  By Brian Dennehy

  Membership Access | gold

  Sector analysis

• 03 Dec

  The Cautious Investor Conundrum – Cash Alternatives

  03 Dec

  Stirring inflation, policy changes, COVID unlock, geo-political tensions… what does all of this mean for a typically cautious investor?

  By Ruairi Dennehy

  Membership Access | gold

  Market commentary

• 03 Dec

  Global – Dynamic Portfolio Review

  03 Dec

  This week we review our Dynamic Global Portfolio. We explore how the portfolio is made and its performance, both short term and long term.

  By Ben Debney

  Membership Access | gold

  Dynamic Portfolios

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• >
• >>